

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: The sequence in Fig. 2A does not have a SEQ ID NO.

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

SEQUENCE LISTING

<110> Allen, Keith D.
Matthews, William
Moore, Mark

<120> TRANSGENIC MICE CONTAINING GPRC5B-LIKE
GENE DISRUPTIONS

<130> R-390

<140> To Be Assigned
<141> Herewith

<150> US 60/256,199
<151> 2000-12-13

<150> US 60/280,359
<151> 2001-03-29

<160> 4

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 2870
<212> DNA
<213> Homo sapiens

<400> 1
aggtcgcagg cgggcgtgcg tggagcgffff gcccgcggccg cgccgcagag atgtgactcg 60
ggccgaaggc cagctggagc gtcggcgctg cggggccgcg ggggtcgaat gttcgtggca 120
tcagagagaa agatgagagc tcaccagggtg ctacaccccttcc tcctgtctt cgtgtatcacc 180
tcggtgtggcct ctgaaaacgc cagcacatcc cgaggctgtg ggctggaccc cttccctcag 240
tacgtgtccc tgtgcgaccc ggacgccccatc tggggcattt tggtggaggc ggtggccggg 300
gcgggcgcgcc tgatcacact gctcctgtat ctcatccctcc tggtgcggct gcccttcatc 360
aaggagaagg agaagaagag ccctgtgggc ctccacttcc ttgttcctcct ggggaccctg 420
ggcctcttgc ggctgtacgtt tgccttcatc atccaggagg acgagaccat ctgctctgtc 480
cgccgcgttcc tctggggcgt cctctttgcg ctctgtcttct cctgcctgtc gagccaggca 540
tggcgcgtgc ggaggctggt gccggcatggc acggggccccgg cgggctggca gctgggtggc 600
ctggcgcgtgt gcctgtatgtt ggtcaagtc atcatcgctg tggagtggt ggtgctcacc 660
gtgctgcgtg acacaaggcc agcctgcgcc tacgagccca tggactttgt gatggccctc 720
atctacgaca tggtaactgtt tgggttcacc ctggggctgg ccctcttcac tctgtgcggc 780
aagttcaaga ggtggaagct gaacggggcc ttccctccatc tcacagcattt cctctctgt 840
ctcatctggg tggcctggat gaccatgtac ctcttcggca atgtcaagct gcagcagggg 900
gatgcctgga acgaccccccac ctggccatc acgctggcgg ccagcggctg ggtcttcgtc 960
atcttccacg ccatccctga gatccactgc acccttctgc cagccctgcgaa ggagaacacg 1020
cccaactact tcgacacgtc gcagcccaagg atgcgggaga cggccttcga ggaggacgtg 1080
cagctggcgc gggcttatat ggagaacaag gccttctcca tggatgaaca caatgcagct 1140
ctccgaacacg caggatttcc caacggcagc ttggggaaaaa gacccagtgg cagcttgggg 1200
aaaagaccca ggcgtccgtt tagaagcaac gtgtatcagc caactgagat ggccgtcgtg 1260
ctcaacgggtg ggaccatcccc aactgtcccg ccaagtccaca caggaagaca cctttggta 1320
aagactttaa gttccagaga atcagaattt ctcttaccga tttgcctccc tggctgtgtc 1380
tttcttgagg gagaatcgg taacagtgc cgaaccaggc cgcctcacag ccaggaaatt 1440
tggaaatctt agccaagggg atttcgtgtt aatgtgaaca ctgacgaact gaaaagctaa 1500
caccgactgc cgcgcctcc cctgccacac acacagacac gtaataccag accaacctca 1560
atccccgcaa actaaagcaa agctaattgc aaatagtatt aggctcactg gaaaatgtgg 1620
ctggaaagac tggttcatcc tctgggggtt gaaacagaacc aaattcacag ctgggtggcc 1680
agactgggtt tgggtggagg tggggggctc ccactttat cacctctccc cagcaagtgc 1740
tggacccacg gtagccttcc ggagatgacc gttgcgttga ggacaaatgg ggactttgcc 1800

accggcttgc ctgggtggtt gcacattca ggggggtcag gagagttaag gaggttgtgg 1860
 gtgggattcc aaggtagggc ccaactgaat cggtgggtga gctttatagc cagtagaggt 1920
 ggaggggaccc tggcatgtgc caaagaagag gcctctggg tgatgaagtg accatcacat 1980
 ttggaaaagtg atcaaccact gttccttcta tgggctctt gctctaattgt ctatggtgag 2040
 aacacaggcc cgcgccttc cttgttagag ccataaaaaat attctggctt ggggcagcag 2100
 tcccttcttc cttgtatcat ctgcctctgt tcctacactt acgggttat ctccaaatcc 2160
 tctcccaatt ttatccctt attcattca agagctccaa tggggtctcc agctgaaagc 2220
 ccctccggga ggcagggtgg aaggcaggca ccacggcagg tttccgcga tgatgtcacc 2280
 tagcagggtc tcaggggttc ccactaggat gcagagatga cctctcgctg cctcacaagc 2340
 agtgcacact cgggtcttc cgggtgttat ggtaaaaatt cctggatgga atggatcaca 2400
 tgagggttgc ttgttgcttt tggaggggtgt gggggatatt ttgtttgtt ttttctgcag 2460
 gttccatgaa aacagccctt ttccaagccc attgtttctg tcatgtttc catctgtcct 2520
 gagcaagtca ttcccttgcattt attagcatt tcaaacatct cggccattca aagccccat 2580
 gttctctgca ctgtttggcc agcataaacct cttagcatcga ttcaaagcag agtttaacc 2640
 tgacggcatg gaatgtataa atgaggggtgg gtccttctgc agataactcta atcactacat 2700
 tgcttttcttataaaaactac ccataagcct ttaaccttta aagaaaaatg aaaaaggta 2760
 gtgtttgggg gcccggggag gactgaccgc ttcatagc agtacgtctg agctgagtat 2820
 gttcaataa acctttgat atttctcaaa aaaaaaaaaa aaaaaaaaaa 2870

<210> 2
 <211> 403
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Phe Val Ala Ser Glu Arg Lys Met Arg Ala His Gln Val Leu Thr
 1 5 10 15
 Phe Leu Leu Leu Phe Val Ile Thr Ser Val Ala Ser Glu Asn Ala Ser
 20 25 30
 Thr Ser Arg Gly Cys Gly Leu Asp Leu Leu Pro Gln Tyr Val Ser Leu
 35 40 45
 Cys Asp Leu Asp Ala Ile Trp Gly Ile Val Val Glu Ala Val Ala Gly
 50 55 60
 Ala Gly Ala Leu Ile Thr Leu Leu Leu Met Leu Ile Leu Leu Val Arg
 65 70 75 80
 Leu Pro Phe Ile Lys Glu Lys Glu Lys Ser Pro Val Gly Leu His
 85 90 95
 Phe Leu Phe Leu Leu Gly Thr Leu Gly Leu Phe Gly Leu Thr Phe Ala
 100 105 110
 Phe Ile Ile Gln Glu Asp Glu Thr Ile Cys Ser Val Arg Arg Phe Leu
 115 120 125
 Trp Gly Val Leu Phe Ala Leu Cys Phe Ser Cys Leu Leu Ser Gln Ala
 130 135 140
 Trp Arg Val Arg Arg Leu Val Arg His Gly Thr Gly Pro Ala Gly Trp
 145 150 155 160
 Gln Leu Val Gly Leu Ala Leu Cys Leu Met Leu Val Gln Val Ile Ile
 165 170 175
 Ala Val Glu Trp Leu Val Leu Thr Val Leu Arg Asp Thr Arg Pro Ala
 180 185 190
 Cys Ala Tyr Glu Pro Met Asp Phe Val Met Ala Leu Ile Tyr Asp Met
 195 200 205
 Val Leu Leu Val Val Thr Leu Gly Leu Ala Leu Phe Thr Leu Cys Gly
 210 215 220
 Lys Phe Lys Arg Trp Lys Leu Asn Gly Ala Phe Leu Leu Ile Thr Ala
 225 230 235 240
 Phe Leu Ser Val Leu Ile Trp Val Ala Trp Met Thr Met Tyr Leu Phe
 245 250 255
 Gly Asn Val Lys Leu Gln Gln Gly Asp Ala Trp Asn Asp Pro Thr Leu
 260 265 270
 Ala Ile Thr Leu Ala Ala Ser Gly Trp Val Phe Val Ile Phe His Ala
 275 280 285

Ile Pro Glu Ile His Cys Thr Leu Leu Pro Ala Leu Gln Glu Asn Thr
290 295 300
Pro Asn Tyr Phe Asp Thr Ser Gln Pro Arg Met Arg Glu Thr Ala Phe
305 310 315 320
Glu Glu Asp Val Gln Leu Pro Arg Ala Tyr Met Glu Asn Lys Ala Phe
325 330 335
Ser Met Asp Glu His Asn Ala Ala Leu Arg Thr Ala Gly Phe Pro Asn
340 345 350
Gly Ser Leu Gly Lys Arg Pro Ser Gly Ser Leu Gly Lys Arg Pro Ser
355 360 365
Ala Pro Phe Arg Ser Asn Val Tyr Gln Pro Thr Glu Met Ala Val Val
370 375 380
Leu Asn Gly Gly Thr Ile Pro Thr Ala Pro Pro Ser His Thr Gly Arg
385 390 395 400
His Leu Trp

<210> 3
<211> 200
<212> DNA
<213> Artificial Sequence

<220>
<223> Targeting Vector

<400> 3
tgatgctcat tctccttagtg agactaccct tcatcaagga caagggaaagg aagcggccctg 60
tgtgcctcca tttcctcttc ctgctgggga ccctgggcct ctttggcctg acgtttgct 120
tcatcatcca gatggacgag acaatctgct ccatccgacg cttccctctgg ggtgtcctct 180
tcgcgcctcg ctttccgct 200

<210> 4
<211> 200
<212> DNA
<213> Artificial Sequence

<220>
<223> Targeting Vector

<400> 4
gtgagcctgg cactgtgcct gatgctggtg caggtcatca ttgccactga gtggctggtg 60
ctgactgtgc tgcgtgacac gaagccagcc tgcgcctacg agccccatgga ttttgtatg 120
gcgcctcatct acgacatggt gctgctggcc atcacccctgg cccagtcctt cttcacgctg 180
tgtggcaagt tcaaacggtg 200